Alexey Strygin is a seasoned bioentrepreneur with over a decade of experience in the longevity biotechnology arena. Previously serving as the CEO and co-founder of Gray Matter—where he led efforts to develop innovative therapeutic peptides aimed at combating age‐related cognitive decline—Alexey has dedicated his career to extending healthy human lifespan through cutting‐edge research and technology. His work is characterized by a blend of scientific rigor and entrepreneurial vision, positioning him as a notable thought leader in the field of aging and longevity.

​Building on his extensive background in biotech, Alexey recently founded the Longevity Economics Institute—a pioneering initiative designed to put quantitative rigor behind the economic impact of aging. The Institute focuses on developing robust economic projections, pharmacoeconomic analyses, and policy justifications that aim to convince governments and decision makers to channel more funding into longevity research. In parallel, Alexey is involved in innovative projects like Viva City, which seeks to establish special regulatory zones that accelerate the development of longevity biotech innovations by rethinking traditional clinical trial and drug approval processes. His vision is to reshape the financial and regulatory landscape to foster transformative breakthroughs in aging science.